Form 4 for ACRS Aclaris Therapeutics, Inc.
Accepted 2026-01-05 00:00:00 ET · period of report 2026-01-02 · accession 0001604457-26-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-05 | 2026-01-02 | ACRS | Walker Neal | CEO, Dir | M - OptEx | — | +29.1K | 1.51M | +2% | — |
| D | 2026-01-05 | 2026-01-02 | ACRS | Walker Neal | CEO, Dir | F - Tax | $2.88 | -9,952 | 1.50M | -0.7% | -$28.7K |
| D | 2026-01-05 | 2026-01-02 | ACRS | Walker Neal | CEO, Dir | M - OptEx | $0.00 | -29.1K | 30.0K | -49% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-02 | M | A | 29,150 | — | 1,508,974 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. |
| 2 | Common | Common Stock | 2026-01-02 | F | D | 9,952 | $2.88 | 1,499,022 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2026-01-02 | M | D | 29,150 | $0.00 | 30,034 | D | — · — to — | 29,150 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. (F3) The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. |